Comparison of Safety and Efficacy of de Novo Everolimus

NCT04906304 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus Infections

Interventions

DRUG: Everolimus Pill
DRUG: Sandimmun (Neoral) dose plus cellcept

Sponsor

Shahid Beheshti University of Medical Sciences